IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Theravance Biopharma Inc

CUSIP: 107532277 | 2 institutional holders

Quarters

Q2 2018Q2 2014
CompareDetailedHistoricalFundsOptions13D/13GPeersTargetingTrading SummaryProfile

Institutional Holders — Q2 2018

Advent Capital Management20,000
0.0% of portfolio›$454
StyleTurnoverLocationFiled
Advent Capital Management
20,000$4540.0%GrowthMediumNew York, NY2018-08-14